# US 2010/0247514 A1 · Gamma secretase modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247514 A1
- Document ID: US20100247514A1
- Status: Published application
- Kind: A1
- Application number: 12/598,704
- Filed: 2008-05-05
- Published: 2010-09-30
- Earliest claimed: 2007-05-07
- Assignees: Schering Corporation
- Inventors: Zhaoning Zhu; William J. Greenlee; Zhong-Yue Sun; Gioconda Gallo; Theodros Asberom; Xianhai Huang; Xiaohong Zhu; Mark D. McBriar; Dmitri A. Pissarnitski; Zhiqiang Zhao; Ruo Xu; Hongmei Li; Anandan Palani; Johannes H. Voigt; Robert D. Mazzola, JR.; John Clader; Hubert Josien; Jun Qin
- Web page: https://patentgrep.com/patent/US20100247514A1

## CPC

- C07D 413/10: linked by a carbon chain containing aromatic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/14: containing three or more hetero rings
- C07D 498/04: Ortho-condensed systems
- C07D 498/10: Spiro-condensed systems
- C07D 498/20: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

## Claims

### Claim 1

A compound, or pharmaceutically acceptable salts, solvates, esters or prodrugs of said compound, said compound having the general structure shown in the formula:
wherein:
U is
or N;
G is O or S;
V is selected from the group consisting of a bond, O, —C(O)—, and N(R14);
R1 is selected from the group consisting of H, halo, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl- can be unsubstituted or optionally independently substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
R2 is selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl- can be unsubstituted or optionally independently substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
or, alternatively, R1 and R2 may be joined together to form a C5-C8 cycloalkyl or a 5-8 membered heterocyclyl moiety, with each of said cycloalkyl or heterocyclyl moiety being unsubstituted or optionally independently being substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
or, alternatively, R1 and R8 are taken together to form a bond;
R5, R6 and R7 can be the same or different, each being independently selected from the group consisting of H, —C(O)R15, —C(O)OR15, —C(O)N(R15)(R16), —C(═NOR15)R16, alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl- can be unsubstituted or optionally independently substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
or alternately, R6 and R7 can be joined together to form a carbocyclic spirocyclic moiety or a heterocyclic spirocyclic moiety wherein each of said carbocyclic spirocyclic moiety and heterocyclic spirocyclic moiety can be: (i) unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below, or (ii) fused with an aryl, heteroaryl, cycloalkyl or heterocycloalkyl ring, wherein each of said carbocyclic spirocyclic moiety, heterocyclic spirocyclic moiety, aryl, heteroaryl, cycloalkyl and heterocycloalkyl ring can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
R8 is selected from the group consisting of H, halo, —CN, —OR15, —C(O)R15, —C(O)OR15, —C(O)N(R15)(R16), —SR15, —S(O)N(R15)(R16), —CH(R15)(R16), —S(O)2N(R15)(R16), —C(═NOR15)R16, —P(O)(OR15)(OR16), —N(R15)(R16), -alkyl-N(R15)(R16), —N(R15)C(O)R16, —CH2—N(R15)C(O)R16, —CH2—N(R15)C(O)N(R16)(R17), —CH2—R15; —CH2N(R15)(R16), —N(R15)S(O)R16, —N(R15)S(O)2R16, —CH2—N(R15)S(O)2R16, —N(R15)S(O)2N(R16)(R17), —N(R15)S(O)N(R16)(R17), —N(R15)C(O)N(R16)(R17), —CH2—N(R15)C(O)N(R16)(R17), —N(R15)C(O)OR16, —CH2—(R15)C(O)OR16, —S(O)R15, —N3, —NO2 and —S(O)2R15, alkyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, with each of said alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl- being unsubstituted or optionally independently substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
R10 is selected from the group consisting of a bond, alkyl-, aryl-, arylalkyl-, arylalkenyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclyalkyl- and the moieties:
where X is O, N(R14) or S;
wherein each of said alkyl-, aryl-, arylalkyl-, arylalkenyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- heterocyclyalkyl- and the above-noted moieties for R10 can be unsubstituted or optionally independently substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of the moieties shown below;
or, alternatively, R8 and R10, together with the carbon atom to which they are bound, can form a C4-C7 carbocyclic (e.g., cycloalkyl) ring, or a 4-7 membered heterocyclyl ring, or a C4-C7 carbocyclenyl (e.g., cycloalkenyl) ring, or a 4-7 membered heterocyclenyl ring; and wherein said carbocyclic ring, heterocyclyl ring, carbocyclenylring, or heterocyclenyl ring is optionally substituted with 1-5 independently selected R21 substituents;
R9 is selected from the group consisting of alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl- can be unsubstituted or optionally independently substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of the moieties shown below;
R14 is selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, —CN, —C(O)R15, —C(O)OR15, —C(O)N(R15(R16), —S(O)N(R15)(R16), —S(O)2N(R15)(R16), —C(═NOR15)R16, and —P(O)(OR15)(OR16), and wherein each of said alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl groups is optionally substituted with 1-5 substituents independently selected from the group consisting of the moieties shown below;
R15, R16 and R17 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, R18-alkyl, R18-cycloalkyl, R18-cycloalkylalkyl, R18-heterocyclyl, R18-heterocyclylalkyl, R18-aryl, R18-arylalkyl, R18-heteroaryl and R18-heteroarylalkyl;
R18 is 1-5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, —NO2, halo, heteroaryl, —CF3, —CN, —C(O)R19, —C(O)OH, —C(O)OR19, —C(O)NHR20, —C(O)NH2, —C(O)NH2—C(O)N(alkyl)2, —C(O)N(alkyl)(aryl), —C(O)N(alkyl)(heteroaryl), —SR19, —S(O)2R20, —S(O)NH2, —S(O)NH(alkyl), —S(O)N(alkyl)(alkyl), —S(O)NH(aryl), —S(O)2NH2, —S(O)2NHR19, —S(O)2NH(heterocyclyl), —S(O)2N(alkyl)2, —S(O)2N(alkyl)(aryl), —OCF3, —OH, —OR20, —O-heterocyclyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH2, —NHR20, —N(alkyl)2, —N(arylalkyl)2, —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R20, —NHC(O)NH2, —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O)2R20, —NHS(O)2NH(alkyl), —NHS(O)2N(alkyl)(alkyl), —N(alkyl)S(O)2NH(alkyl) and —N(alkyl)S(O)2N(alkyl)(alkyl);
or, alternately, two R18 moieties on adjacent carbons can be linked together to form:
R19 is alkyl, cycloalkyl, aryl, arylalkyl or heteroarylalkyl;
R20 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
wherein each of the carbocyclic spirocyclic, heterocyclic spirocyclic, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R1, R2, R5, R6, R7, R8, R9, R10 and R14 are independently unsubstituted or substituted by 1 to 5 R21 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, —CN, —OR15, —C(O)R15, —C(O)OR15, —C(O)N(R15)(R16), —SR15, —S(O)N(R15)(R16), —CH(R15)(R16), —S(O)2N(R15)(R16), —C(═NOR15)R16, —P(O)(OR15)(OR16), —N(R15)(R16), -alkyl-N(R15)(R16), —N(R15)C(O)R16, —CH2—N(R15)C(O)R16, —CH2—N(R15)C(O)N(R16)(R17), —CH2—R15, —CH2N(R15)(R16), —N(R15)S(O)R16, —N(R15)S(O)2R16, —CH2N(R15)S(O)2R16, —N(R15)S(O)2N(R16)(R17), —N(R15)S(O)N(R16)(R17), —N(R15)C(O)N(R16)(R17), —CH2—N(R15)C(O)N(R16)(R17), —N(R15)C(O)OR16, —CH2—N(R15)C(O)OR16, —S(O)R15, —N3, —NO2 and —S(O)2R15;
wherein each of the alkyl, cycloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R21 are independently unsubstituted or substituted by 1 to 5 R22 groups independently selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, halo, —CF3, —CN, —OR15, —C(O)R15, —C(O)OR15, -alkyl-C(O)OR15, C(O)N(R15)(R16), —SR15, —S(O)N(R15)(R16), —S(O)2N(R15)(R16), —C(═NOR15)R16, —P(O)(OR15)(OR16), —N(R15)(R16), -alkyl-N(R15)(R16), —N(R15)C(O)R16, —CH2—N(R15)C(O)R16, —N(R15)S(O)R16, —N(R15)S(O)2R16, —CH2—N(R15)S(O)2R16, —N(R15)S(O)2N(R16)(R17), —N(R15)S(O)N(R16)(R17), —N(R15)C(O)N(R16)(R17), —CH2N(R15)C(O)N(R16)(R17), —N(R15)C(O)OR16, —CH2—N(R15)C(O)OR16, —N3, —NO2, —S(O)R15 and —S(O)2R15.

### Claim 2

A compound, or pharmaceutically acceptable salts, solvates, esters or prodrugs of said compound, said compound having the general structure shown in the formula:
wherein:
U is C or N—;
R1 is selected from the group consisting of: H, halo, alkyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups;
R2 is selected from the group consisting of: H, alkyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups;
or, alternatively, R1 and R2 may be joined together to form a C5-C8 cycloalkyl or a 5-8 membered heterocyclyl moiety, with each of said cycloalkyl or heterocyclyl moiety being unsubstituted or optionally independently being substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups;
R6 and R7 can be the same or different, each being independently selected from the group consisting of H, alkyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, wherein each of said alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with 1-5 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy, alkoxy, -aryl and -heteroaryl groups;
or alternately, R6 and R7 can be joined together to form a cyclic moiety (spirocyclic) which can be optionally substituted or fused with an aryl or heteroaryl ring, with each of said aryl or heteroaryl ring being unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy, alkoxy, aryl and heteroaryl groups;
R8 is selected from the group consisting of H, alkyl, cycloalkyl, aryl and heteroaryl, with each of said alkyl, cycloalkyl, aryl and heteroaryl being unsubstituted or optionally independently substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups;
R10 is aryl or heteroaryl wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups; and
R9 is heteroaryl which can be unsubstituted or optionally independently substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups.

### Claim 3 (depends on 1)

The compound of claim 1, wherein U is C(R5).

### Claim 4 (depends on 1)

The compound of claim 1, wherein U is N.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of H, alkyl, alkoxyalkyl-, (4-alkoxy)phenylmethyl-, and arylalkyl-.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R2 is selected from the group consisting of: methyl, 3-methoxypropyl-, phenylmethyl-, and (4-methoxy)phenylmethyl-.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R2 is selected from the group consisting of: H, —(CH2)3OCH3, —CH3, —CH2CH3, —(CH2)2OCH3, —(CH2)2CH(CH3)2, —CH2CH(CH3)CH2CH3, —CH2CH2CH3,

### Claim 8 (depends on 1)

The compound of claim 1, wherein U is N and R2 is 3-methoxypropyl-.

### Claim 9 (depends on 1)

The compound of claim 1, wherein:
(a) R1 is selected from the group consisting of: H and alkyl, or
(b) R1 is selected from the group consisting of: H and methyl, or
(c) R1 is methyl.

### Claim 10 (depends on 1)

The compound of claim 1, wherein:
(a) R1 and R2 are joined together to form a cyclopentyl ring, which is unsubstituted, or
(b) wherein R1 and R2 are joined together to form a cyclopentyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups, or
(c) R1 and R2 are joined together to form a cyclohexyl ring, which is unsubstituted, or
(d) R1 and R2 are joined together to form a cyclohexyl ring, which is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups.

### Claim 11 (depends on 1)

The compound of claim 1, wherein:
(a) U is N, and R1 and R2 are joined together to form a piperidinyl ring including the N of U as the nitrogen of said piperidinyl ring, which is unsubstituted, or
(b) U is N, and R1 and R2 are joined together to form a piperidinyl ring including the N of U as the nitrogen of said piperidinyl ring, wherein said piperidinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups.

### Claim 12 (depends on 1)

The compound of claim 1, wherein:
(a) U is N, and R1 and R2 are joined together to form a pyrrolidinyl ring including the N of U as the nitrogen of said pyrrolidinyl ring, which is unsubstituted, or
(b) U is N, and R1 and R2 are joined together to form a pyrrolidinyl ring including the N of U as the nitrogen of said pyrrolidinyl ring, wherein said pyrrolidinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups.

### Claim 13 (depends on 1)

The compound of claim 1, wherein:
(a) U is N, and R1 and R2 are joined together to form a piperazinyl ring including the N of U as a nitrogen of said piperazinyl ring, which is unsubstituted, or
(b) U is N, and R1 and R2 are joined together to form a piperazinyl ring including the N of U as a nitrogen of said piperazinyl ring, wherein said piperazinyl ring is substituted with 1-3 substituents which can be the same or different, each being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups.

### Claim 14 (depends on 1)

The compound of claim 1 wherein R6 is selected from the group consisting of: H, alkyl, cycloalkyl, —C(O)OR15, alkyl substituted with 1-3 halos, —C(O)R15, and alkyl substituted with —OR15.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R6 is selected from the group consisting of: H, methyl, methyl substituted with —OH, and methyl substituted with OCH3.

### Claim 16 (depends on 1)

The compound of claim 1 wherein R7 is selected from the group consisting of: (a) aryl substituted with 1-3 R21 moieties, (b) aryl substituted with —OR15 wherein R15 is (i) an alkyl substituted with 1-3 halos, or (ii) alkyl, (c) aryl, (d) aryl substituted with alkyl wherein said alkyl is substituted with 1-3 halos, (e) aryl substituted with aryl, (f) alkyl, (g) heteroaryl, (h) arylalkyl-, and (i) cycloalkyl).

### Claim 17 (depends on 1)

The compound of claim 1 wherein:
(a) R7 is aryl, or
(b) R7 is an unsubstituted phenyl, or
(c) R7 is a phenyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy, alkoxy, aryl and heteroaryl groups, or
(d) R7 is unsubstituted naphthyl, or
(e) R7 is naphthyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy, alkoxy, aryl and heteroaryl groups, or
(f) R7 is unsubstituted biphenyl, or
(g) R7 is biphenyl which is substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups.

### Claim 18 (depends on 1)

The compound of claim 1, wherein:
(a) R6 is H and R7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups, or
(b) wherein R6 is methyl, and R7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups, or
(c) R6 is H, and R7 is a phenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups, or
(d) R6 is methyl, and R7 is a biphenyl which can be unsubstituted or optionally independently substituted with 1-4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy and alkoxy groups, or
(e) R6 is alkyl substituted with 1-5 independently selected R21 moieties, and R7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy, alkoxy, aryl and heteroaryl groups, or
(f) R6 is alkyl substituted with one R21 moiety, and R7 is phenyl substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, —CN, —NH2, —NH(alkyl), —N(alkyl)2, hydroxy, alkoxy, aryl and heteroaryl groups,
(g) R6 and R7 are joined to form the spirocyclic unit:
(h) R6 and R7 are joined to form the spirocyclic unit:

### Claim 19 (depends on 1)

The compound of claim 1, wherein R8 is H.

### Claim 20 (depends on 1)

The compound of claim 1, wherein R8 is alkyl.

### Claim 21 (depends on 1)

The compound of claim 1, wherein R8 is methyl.

### Claim 22 (depends on 1)

The compound of claim 1, wherein R10 is aryl.

### Claim 23 (depends on 1)

The compound of claim 1 wherein:
(a) R10 is aryl substituted with 1 to 3 independently selected R21 moieties, or
(b) R10 is aryl substituted with 1 to 3 R21 moieties, wherein each R21 moiety is the same or different —OR15 group, or
(c) R10 is aryl substituted with 1 R21 moiety, or
(d) R10 is aryl substituted with one R21 moiety, and said R21 moiety is —OR15, or
(e) R10 is aryl substituted with one R21 moiety, said R21 moiety is —OR15, and said R15 is alkyl, or
(f) R10 is aryl substituted with one R21 moiety, said R21 moiety is —OR15, said R15 is alkyl, and said alkyl is methyl.

### Claim 24 (depends on 1)

The compound of claim 1, wherein:
(a) R10 is phenyl, or
(b) R10 is phenyl substituted with 1 to 3 independently selected R21 moieties, or
(c) R10 is phenyl substituted with 1 to 3 R21 moieties, wherein each R21 moiety is the same or different —OR15 group, or
(d) R10 is phenyl substituted with 1 R21 moiety, or
(e) R10 is phenyl substituted with one R21 moiety, and said R21 moiety is —OR15, or
(f) R10 is phenyl substituted with one R21 moiety, said R21 moiety is —OR15, and said R15 is alkyl, or
(g) R10 is phenyl substituted with one R21 moiety, said R21 moiety is —OR15, said R15 is alkyl, and said alkyl is methyl.

### Claim 25 (depends on 1)

The compound of claim 1, wherein R10 is heteroaryl.

### Claim 26 (depends on 1)

The compound of claim 1, wherein;
(a) R9 is unsubstituted heteroaryl,
(b) R9 is heteroaryl which is substituted with 1-3 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, CN, NH2, NH(alkyl), N(alkyl)2, hydroxy and alkoxy groups, or
(c) R9 is imidazol-1-yl, or
(d) R9 is 4-methyl-imidazol-1-yl, or
(e) R9 is 5-chloro-4-methyl-imidazol-1-yl.

### Claim 27 (depends on 1)

The compound of claim 1 wherein R10 is selected from the group consisting of:

### Claim 28 (depends on 1)

The compound of claim 1 wherein:
(a) the —R10-R9 moiety is:
(b) the —R10-R9 moiety is:
(c) the —R10-R9 moiety is:

### Claim 29 (depends on 1)

The compound of claim 1 wherein;
(a) the R9-R10— moiety is:
(b) the R9-R10— moiety is:
(c) the R9-R10— moiety is:
(d) the R9-R10— moiety is:
(e) the R9-R10— moiety is:
(f) the R9-R10— moiety is:
(g) the R9-R10— moiety is:

### Claim 30 (depends on 1)

The compound of claim 1 having the formula:

### Claim 31 (depends on 1)

The compound of claim 1 having the formula:

### Claim 32 (depends on 1)

The compound of claim 1 having the formula:

### Claim 33 (depends on 1)

The compound of claim 1 having the formula:

### Claim 34

Another embodiment of this invention is directed to the compound:

### Claim 35 (depends on 1)

The compound of claim 1 having the formula:

### Claim 36 (depends on 1)

The compound of claim 1 having the formula:

### Claim 37 (depends on 1)

The compound of claim 1 having the formula:

### Claim 38 (depends on 1)

The compound of claim 1 having the formula:

### Claim 39 (depends on 1)

The compound of claim 1 having the formula:

### Claim 40 (depends on 1)

The compound of claim 1 having the formula:

### Claim 41 (depends on 1)

The compound of claim 1 having the formula:

### Claim 42 (depends on 1)

The compound of claim 1 having the formula:

### Claim 43 (depends on 1)

The compound of claim 1 having the formula:

### Claim 44 (depends on 1)

The compound of claim 1 having the formula:

### Claim 45 (depends on 1)

The compound of claim 1 having the formula:

### Claim 46 (depends on 1)

The compound of claim 1 having the formula:

### Claim 47 (depends on 1)

The compound of claim 1 having the formula:

### Claim 48 (depends on 1)

The compound of claim 1 having the formula:

### Claim 49 (depends on 1)

The compound of claim 1 having the formula:

### Claim 50 (depends on 1)

The compound of claim 1 having the formula:

### Claim 51 (depends on 1)

The compound of claim 1 having the formula:

### Claim 52 (depends on 1)

The compound of claim 1 having the formula:

### Claim 53 (depends on 1)

The compound of claim 1 having the formula:

### Claim 54 (depends on 1)

The compound of claim 1 having the formula:

### Claim 55 (depends on 1)

The compound of claim 1 having the formula:

### Claim 56 (depends on 1)

The compound of claim 1 having the formula:

### Claim 57 (depends on 1)

The compound of claim 1 having the formula:

### Claim 58 (depends on 1)

The compound of claim 1 having the formula:

### Claim 59 (depends on 1)

The compound of claim 1 having the formula:

### Claim 60 (depends on 1)

The compound of claim 1 having the formula:

### Claim 61 (depends on 1)

The compound of claim 1 having the formula:

### Claim 62

A compound selected from the group consisting of: compounds 1 to 167.

### Claim 63 (depends on 62)

The compound of claim 62 wherein said compound is a pharmaceutically acceptable salt of the compound of claim 62.

### Claim 64 (depends on 62)

The compound of claim 62 wherein said compound is a solvate of the compound of claim 62.

### Claim 65 (depends on 62)

The compound of claim 62 wherein said compound is an ester of the compound of claim 62.

### Claim 66 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 67 (depends on 62)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 62, and a pharmaceutically acceptable carrier.

### Claim 68 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier, and and an effective amount of one or more other pharmaceutically active drugs selected form the group consisting of: (a) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue, (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase.

### Claim 69 (depends on 62)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 62, and a pharmaceutically acceptable carrier, and and an effective amount of one or more other pharmaceutically active drugs selected form the group consisting of: (a) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue, (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase.

### Claim 70 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors.

### Claim 71 (depends on 62)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 62, and a pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors.

### Claim 72 (depends on 1)

A pharmaceutical composition:
(1) comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, or
(2) comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of one or more other pharmaceutically active drugs selected form the group consisting of: (a) drugs useful for the treatment of Alzheimer's disease, (b) drugs useful for inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue, (c) drugs useful for treating neurodegenerative diseases, and (d) drugs useful for inhibiting gamma-secretase, or
(3) comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of one or more BACE inhibitors,
(4) comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and effective amount of one or more cholinesterase inhibitors, or
(5) comprising a therapeutically effective amount of at least one compound of claim 1, and at least one pharmaceutically acceptable carrier, and effective amount of one or more cholinesterase inhibitors, or
(6) comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and effective amount of one or more BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABAA inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors and cholesterol absorption inhibitors, or
(7) comprising a therapeutically effective amount of at least one compound of claim 1, and at least one pharmaceutically acceptable carrier, and effective amount of one or more BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABAA inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors and cholesterol absorption inhibitors, or
(8) comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, or ester thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of donepezil hydrochloride, or
(9) comprising a therapeutically effective amount of at least one compound of claim 1, and at least one pharmaceutically acceptable carrier, and an effective amount of donepezil hydrochloride.

### Claim 73 (depends on 1)

A method of modulating gamma-secretase comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of such treatment.

### Claim 74 (depends on 1)

A method of treating one or more neurodegenerative diseases, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment.

### Claim 75 (depends on 1)

A method of inhibiting the deposition of amyloid protein in, on or around neurological tissue, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment.

### Claim 76 (depends on 1)

A method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment.

### Claim 77 (depends on 62)

A method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 62 to a patient in need of treatment.

### Claim 78 (depends on 1)

A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment.

### Claim 79 (depends on 62)

A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of claim 62 to a patient in need of treatment.

### Claim 80 (depends on 1)

A method of (a) modulating gamma-secretase, (b) treating one or more neurodegenerative diseases, (c) inhibiting the deposition of amyloid protein in, on or around neurological tissue, or (d) treating Alzheimer's disease, comprising administering administering:
(1) an effective amount of a compound of claims 1, and
(2) an effective amount of one or more other pharmaceutically active ingredients selected from the group consisting of: BACE inhibitors, muscarinic antagonists, cholinesterase inhibitors; gamma secretase inhibitors; gamma secretase modulators; HMG-CoA reductase inhibitors; non-steroidal anti-inflammatory agents; N-methyl-D-aspartate receptor antagonists; anti-amyloid antibodies; vitamin E; nicotinic acetylcholine receptor agonists; CB1 receptor inverse agonists or CB1 receptor antagonists; an antibiotic; growth hormone secretagogues; histamine H3 antagonists; AMPA agonists; PDE4 inhibitors; GABAA inverse agonists; inhibitors of amyloid aggregation; glycogen synthase kinase beta inhibitors; promoters of alpha secretase activity; PDE-10 inhibitors and cholesterol absorption inhibitors,
to a patient in need of such treatment.

### Claim 81 (depends on 1)

A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of claim 1, and an effective amount of one or more compounds selected from the group consisting of Aβ antibody inhibitors, gamma secretase inhibitors and beta secretase inhibitors, to a patient in need of such treatment.

### Claim 82 (depends on 1)

A method of treating Alzheimer's disease, comprising administering an effective amount of a compound of claim 1, and an effective amount of one or more BACE inhibitors, to a patient in need of such treatment.

### Claim 83 (depends on 1)

A method of:
(1) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more cholinesterase, to a patient in need of treatment, or
(2) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of donepezil hydrochloride, to a patient in need of treatment, or
(3) treating Alzheimer's disease, comprising administering an effective amount of a compound claim 1, in combination with an effective amount of one or more cholinesterase, to a patient in need of treatment, or
(4) treating Alzheimer's disease, comprising administering an effective amount of a compound of claim 1, in combination with an effective amount of donepezil hydrochloride, to a patient in need of treatment, or
(5) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of (rivastigmine, to a patient in need of such treatment, or
(6) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of tacrine, to a patient in need of such treatment, or
(7) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of a Tau kinase inhibitor, to a patient in need of such treatment, or
(8) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more Tau kinase inhibitors selected from the group consisting of: GSK3beta inhibitors, cdk5 inhibitors, ERK inhibitors, to a patient in need of such treatment, or
(9) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one anti-Abeta vaccination, to a patient in need of such treatment, or
(10) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more APP ligands, to a patient in need of such treatment, or
(11) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more agents that upregulate insulin degrading enzyme and/or neprilysin, to a patient in need of such treatment, or
(12) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more cholesterol lowering agents, to a patient in need of such treatment, or
(13) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more cholesterol lowering agents selected from the group consisting of: Atorvastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, and Ezetimibe, to a patient in need of such treatment, or
(14) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more fibrates, to a patient in need of such treatment, or
(15) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more fibrates selected from the group consisting of, clofibrate, Clofibride, Etofibrate, Aluminium Clofibrate, to a patient in need of such treatment, or
(16) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more LXR agonists, to a patient in need of such treatment, or
(17) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more LRP mimics, to a patient in need of such treatment, or
(18) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more 5-HT6 receptor antagonists, to a patient in need of such treatment, or
(19) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more nicotinic receptor agonists, to a patient in need of such treatment, or
(20) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more H3 receptor antagonists, to a patient in need of such treatment, or
(21) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more histone deacetylase inhibitors, to a patient in need of such treatment, or
(22) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more hsp90 inhibitors, to a patient in need of such treatment, or
(23) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more ml muscarinic receptor agonists, to a patient in need of such treatment, or
(24) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more 5-HT6 receptor antagonists mGluR1 or mGluR5 positive allosteric modulators or agonists, to a patient in need of such treatment, or
(25) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more mGluR2/3 antagonists, to a patient in need of such treatment, or
(26) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of formula I, in combination with an effective amount of one or more anti-inflammatory agents that can reduce neuroinflammation, to a patient in need of such treatment, or
(27) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more Prostaglandin EP2 receptor antagonists, to a patient in need of such treatment, or
(28) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more PAI-1 inhibitors, to a patient in need of such treatment, or
(29) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more agents that can induce Abeta efflux, to a patient in need of such treatment, or
(30) treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of gelsolin, to a patient in need of such treatment,or
(31) treating Downs syndrome, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(32) treating Downs syndrome, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment, or
(33) treating Downs syndrome, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of one or more cholinesterase inhibitors, to a patient in need of treatment.
(34) treating Downs syndrome, comprising administering an effective amount of one or more compounds of claim 1, in combination with an effective amount of donepezil hydrochloride, to a patient in need of treatment, or
(35) treating Downs syndrome, comprising administering an effective amount of a compound of claim 1, in combination with an effective amount of one or more cholinesterase inhibitors, to a patient in need of treatment.
(37) treating Downs syndrome, comprising administering an effective amount of a compound of claim 1, in combination with an effective amount of donepezil hydrochloride, to a patient in need of treatment, or
(38) treating mild cognitive impairment, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(39) treating glaucoma, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(40) treating cerebral amyloid angiopathy, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(41) treating stroke, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(42) This invention also provides a method of treating dementia, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(43) treating microgliosis, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(44) treating brain inflammation, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment, or
(45) treating olfactory function loss, comprising administering an effective amount of one or more compounds of claim 1 to a patient in need of treatment.

### Claim 84 (depends on 1)

A kit comprising, in separate containers, in a single package, pharmaceutical compositions for use in combination, wherein one container comprises an effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier, and another container comprises an effective amount of another pharmaceutically active ingredient, the combined quantities of the compound of claim 1 and the other pharmaceutically active ingredient being effective to: (a) treat Alzheimer's disease, or (b) inhibit the deposition of amyloid protein in, on or around neurological tissue, or (c) treat neurodegenerative diseases, or (d) modulate the activity of gamma-secretase.
